Navigation Links
PDL BioPharma Completes October 1 Special Dividend Payment
Date:10/1/2009

INCLINE VILLAGE, Nev., Oct. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has paid the October 1, 2009 special dividend payment of $0.50 per share to all stockholders owning shares of PDL as of September 17, 2009.

As previously announced, the conversion rate for the Company's 2.00% Convertible Senior Notes due February 15, 2012 was adjusted to 94.447 shares of common stock per $1,000 principal amount, as a result of the dividend payment. The conversion rate for the 2.75% Convertible Subordinated Notes due August 16, 2023 was also adjusted to 131.0339 shares of common stock per $1,000 principal amount.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
2. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
3. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
4. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
5. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
6. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
7. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
8. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
9. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
10. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... -- Hanger, Inc. (NYSE: HGR ) announced today ... for the quarter ended September 30, 2014, on Thursday, ... call to discuss these results is scheduled to begin ... Those wishing to participate should call 1-877-662-6095. A replay ... dialing 1-855-859-2056 and referencing Conference ID # 91880739. ...
(Date:10/17/2014)... , Oct. 17, 2014 UBM Medica US announces ... leading online community and information resource for neurologists and other ... and Alzheimer disease , with discussions of the latest ... 1 million Americans have Parkinson disease , more than the ... Lou Gehrig disease. Diagnosis can be difficult because ...
(Date:10/17/2014)... Oct. 17, 2014 Research and ... "Research and Development Prospect of China Dialysis Market, ... Based on the 2013 version, this update ... about dialysis industry and the relevant effect in ... dialysis industry segmentations. Moreover, it analyzes Chinese private-owned ...
Breaking Medicine Technology:Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3
... WAILEA, Hawaii and SUNNYVALE, Calif., June 27, ... from two open-label, multi-center Phase 2,clinical trials ... Injection, the company's lead product,candidate, in combination ... (docetaxel) as a second-line treatment,for patients with ...
... WIRE)--Jun 27, 2007 - Columbia,Laboratories, Inc. (NASDAQ: ... multi-dose pharmacokinetic study of,vaginally-administered lidocaine, which the ... This 42-subject study was designed to provide ... bioadhesive vaginal lidocaine,formulation at three dose strengths ...
Cached Medicine Technology:Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 2Columbia Laboratories Reports Positive Results from Multi-dose,Pharmacokinetic Study of Vaginally-administered Lidocaine 3
(Date:10/20/2014)... Columbus, OH (PRWEB) October 20, 2014 National ... Ohio Chapter of the American Academy of Pediatrics (Ohio AAP, ... Administration (NHTSA) in encouraging parents of teen drivers to talk ... hit the road. , Motor vehicle crashes are the leading ... 2,055 teen drivers involved in fatal crashes, and 859 (42%) ...
(Date:10/20/2014)... It’s hard to imagine what it’s like to live without ... world, it’s a reality. And while new shoes are considered ... walk barefoot on rocky terrain or sewage-lined streets just to ... , Buckner International's Shoes for Orphan Souls ... to encourage support for Air1 and while also providing new ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... October 20, 2014 Recently, BambooIndustry.com, one ... unveiled its new range of bamboo deckings . ... these natural items; they are now available at deeply ... people, it is hard to overstate the significance of ... attention to online services. The company’s workers are striving ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Having been working ... a good knowledge of customer needs. According to James, one ... covered with dazzling sequins, or with high-low skirts that add ... a huge demand. Recently, LunaDress has unveiled its new selection ... of fact, the company’s brand new items are available in ...
Breaking Medicine News(10 mins):Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2
... that the public will use performance data to choose their ... a paper published on bmj.com today, two experts ... choice is not at present a strong lever for change, ... improved to optimise its effect. Research conducted over the ...
... HealthDay Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- ... of heartburn drugs while they were pregnant did not ... a large Danish study finds. This class of ... as Prilosec (omeprazole), Prevacid (lansoprazole) and Nexium (esomeprazole). All ...
... 24 (HealthDay News) -- Excessive alcohol consumption -- a common ... injury and death, warns the American College of Emergency Physicians ... when they get together with family and friends. "Very ... suffer the loss of a loved one because of an ...
... , WEDNESDAY, Nov. 24 (HealthDay News) -- Parents ... if they,re traveling during the holiday season, an expert warns. ... you can,t plan for everything, being prepared will help keep ... Cahill, an associate professor of pediatrics at Loyola University Chicago ...
... WEDNESDAY, Nov. 24 (HealthDay News) -- A study conducted ... for blacks than it is for whites. In fact, ... one-fifth higher than it is for whites in that state. ... on Smoking and Health at the U.S. Centers for Disease ...
... Americans get ready to travel to holiday gatherings with family and ... them are reminded that there are some things you need to ... pack a copy of all vaccination records so that you can ... those records if you board your pet while going on an ...
Cached Medicine News:Health News:Experts question whether patients will use performance data to choose their care 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 3Health News:Holiday Drinking Can Kill, Experts Warn 2Health News:Preparation Can Help Kids With Nut Allergies Travel Safely 2Health News:Black Smokers May Face Higher Death Risk Than Whites: CDC 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: